UnknownPhase 4

EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy -

Denmark26 participantsStarted 2018-02-15

Plain-language summary

Malnutrition occurs frequently in patients with cancer during and after radiotherapy to the gastrointestinal (GI) area and can lead to negative outcomes. N-3 fatty acids from fish, especially eicosapentaenoic acid (EPA) may possess anticachectic properties. The aim of this study is to investigate the effect of two nutritional interventions; dietary counselling and an oral nutritional supplement (ONS) containing 2.2 g of the n-3 fatty acid EPA (Forticare®) or standard care, including dietary counselling and protein supplementation when needed.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * referred to radiotherapy for dissminated, abdominal cancer * \> 18 years of age * able to understand and comply with the intervention * willingness to participate after oral and written conscent Exclusion Criteria: * conditions precluding evaluations of end-points * dementia * operations planned in the observation period

What they're measuring

Change in weight (%)

Timeframe: 6 weeks

Trial details

NCT IDNCT04687124

SponsorJens Rikardt Andersen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-01

Contact for this trial

Jens R Andersen, MD,MPA

+4523346654 jra@nexs.ku.dk

View on ClinicalTrials.gov More Abdominal Cancer trials